PLYX · Polaryx Therapeutics, Inc.

Polaryx Therapeutics Inc Is A Clinical-Stage Biotechnology Company Committed To The Discovery, Development, And Commercialization Of Novel, Disease-Modifying Therapies For Rare, Pediatric Lsds. Its Therapeutic Approach Focuses On Treating The Underlying Pathophysiology Of These Diseases And Addressing Unmet Needs. The Company'S Therapeutic Pipeline Includes Plx-200, Plx-300, And Plx-100, Which Are Orally Available Small-Molecule Drug Candidates Designed To Address Core Pathological Mechanisms Common To Lsds. The Company Has One Reportable Segment: Lysosomal Storage Disorders. The Lysosomal Storage Disorders Segment Consists Of The Company'S Costs Associated With The Preclinical And Clinical Development Of The Company'S Product Candidates.